EMA’s Clinical Trials Guidance for Enhancing Flexibility During Public Health Emergencies

The European Medicines Agency (EMA) has released draft clinical trials guidance for public consultation from 4 March to 30 April 2026. This guidance outlines regulatory flexibilities to enable the timely initiation and adaptation of clinical trials during public health emergencies (PHEs) declared under Regulation (EU) 2022/2371. It emphasizes a risk-proportionate approach, prioritizing participant safety, data integrity, and robust evidence generation over isolated compassionate use, drawing lessons from the COVID-19 pandemic. Key provisions support expedited assessments, decentralized elements, and platform trial designs to address urgent medical needs efficiently.

Fast-Track Trial Launches and Changes

A core insight from the clinical trials guidance is the prioritization of clinical trials targeting PHE-related conditions, with national competent authorities (NCAs) urged to fast-track assessments while deprioritizing non-urgent trials to preserve capacity. For new trials, sponsors must evaluate logistical feasibility, participant safety, and evidence generation potential, favoring collaborations like platform trials for efficiency in large-scale outbreaks. Ongoing trials can implement substantial modifications (SMs)—such as adding PHE-relevant arms, remote consent, or direct investigational product (IP) shipment to participants—with expedited reviews; urgent safety measures (USMs) allow immediate implementation if participant safety is at risk, followed by SM submission. These measures balance public health benefits against risks, exemplified by adaptations like site transfers or randomized arm adjustments, ensuring trials remain robust without compromising Good Clinical Practice (GCP) standards like those in ICH E6(R3).

Risk-Based Trial Designs in Crises

The guidance builds on EU Clinical Trials Regulation (CTR, Regulation (EU) No. 536/2014) and post-COVID international standards (e.g., ICH E6(R3), E8(R1), E19), promoting risk-based trial design with ‘critical to quality’ factors to maintain data reliability amid disruptions. Methodologies include sponsor-led risk assessments for SMs, ETF scientific advice for complex changes, and proportionate safety monitoring—limiting non-serious adverse event collection in PHE-targeted trials per ICH E19. IP management employs direct-to-participant shipment with strict traceability, data privacy under GDPR, and language-adapted labeling; monitoring shifts to remote or centralized approaches, with pseudonymized source data verification (SDV) in exceptional cases.

Boosting HEOR Through Crisis Adaptations

This guidance enables faster evidence generation on PHE interventions, potentially accelerating market access and reimbursement decisions for diagnostics, therapies, and devices through reliable real-world data from adapted trials. Risk-proportionate flexibilities—like waived non-critical safety data or decentralized IP distribution—could reduce trial costs and timelines, optimizing resource allocation during emergencies and minimizing duplication via EU-wide coordination.

Robust platform trial results could inform downstream technology assessments more rapidly, however, sponsors must document PHE impacts on data gaps or biases per methodological points-to-consider documents, ensuring economic models reflect trial reliability for payers. Overall, these provisions enhance preparedness, potentially lowering long-term public health expenditures by prioritizing scientifically sound trials over fragmented compassionate use, while upholding ethical standards.